For research use only. Not for therapeutic Use.
Maxacalcitol (22-Oxacalcitriol), a vitamin D3 (HY-15398) analog, is an orally active VDR agonist. Maxacalcitol has a limited calcemic effect. Maxacalcitol has the potential for psoriasis and hyperparathyroidism research[1][2][3].
Maxacalcitol (22-Oxacalcitriol; 100 nM; for 24 h) markedly increases the expression of LL-37 mRNA in Ca9-22 cells and modestly but significantly increases in HSC-2, HSC-3, and HSC-4 cells[1].
Maxacalcitol (22-Oxacalcitriol; oral gavage; 15 µg/kg/day; 14 days) followed by GSK 269962 at a single dose of 10 mg/kg, leads to a statistically significant reduction of intercontraction interval and bladder compliance, and an increase in DO index, without any effect on ANVC, FNVC, and VTNVC[2].
Maxacalcitol in a dose of 30 but not 15 µg/kg/day induced reduction in detrusor overactivity
(DO) index, non-voiding contractions frequency (FNVC), and amplitude (ANVC), while increasing volume threshold to elicit non-voiding contractions (VTNVC)[2].
| Catalog Number | I000234 |
| CAS Number | 103909-75-7 |
| Synonyms | (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
| Molecular Formula | C26H42O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1 |
| InChIKey | DTXXSJZBSTYZKE-ZDQKKZTESA-N |
| SMILES | CC(C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)OCCC(C)(C)O |
| Reference | [1]. Hiroyuki Tada, et al. Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Biomed Res. 2016;37(3):199-205. [2]. Andrzej Wróbel, et al. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Jul:93:224.e7-224.e15. [3]. Masaru Karakawa, et al. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. |
